Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab Expanded Access for GPP Flares (Japan)
NCT05200247Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by Boehringer Ingelheim. Started Feb 2022; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT05200247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200247.